Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life

Am J Hematol. 2018 Oct;93(10):E329-E331. doi: 10.1002/ajh.25217. Epub 2018 Sep 30.

Authors

James Norwood¹, Cédric Pastoret², Odile Luycx³, Marie-Françoise Le Coz³, Philippe Moreau³, Adrien Trebouet³, Mathilde Niault³, Vincent Launay⁴, Olivier Allangba⁴, Benoit Bareau⁵, Violaine Doncker⁵, Isabelle Grulois⁶, Dominique Jacomy⁷, Katell Le Dû⁸, Catherine Henry⁹, Estelle Le Pabic¹⁰, Marie-Laure Boulland², Thierry Fest^{2

11}, Thierry Lamy^{1

11}, Martine Escoffre-Barbe^{1

12}

Affiliations

¹ Clinical Hematology Department, Rennes University Hospital, France.
² Biological Hematology Department, Rennes University Hospital, France.
³ Hematology Department, Lorient Hospital, France.
⁴ Hematology Department, St-Brieuc Hospital, France.
⁵ Hematology Department, Cesson Hospital.
⁶ Hematology Department, St-Malo Hospital, France.
⁷ Hematology Department, Laval Hospital, France.
⁸ Hematology Department, Clinique du Mans, France.
⁹ Cytogenetics Department, Rennes University Hospital, France.
¹⁰ Biostatistics Department, Rennes University Hospital, France.
¹¹ University of Rennes 1, Brittany, France.
¹² France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Bordeaux, France.

PMID: 30019460
DOI: 10.1002/ajh.25217

No abstract available

Publication types

Comparative Study
Letter
Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm
Drug Substitution*
Female
Follow-Up Studies
Humans
Imatinib Mesylate / therapeutic use
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Retrospective Studies
Survival Analysis
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate